Delivery Order SPE2DR25D2206-SPE2DR26F9BB6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Orencia 125 mg/ml syringes valued at $9,176.76 on September 15, 2025, with completion scheduled for September 16, 2025. This non-competitive delivery order uses firm fixed pricing and represents a child contract under AmerisourceBergen's larger indefinite delivery contract with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Orencia is a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,316.24 to AmerisourceBergen Drug Corp for Orencia 125 mg/ml syringes, a biologic medication used primarily for rheumatoid arthritis treatment. The contract was awarded on May 8, 2025, with an ultimate completion date of May 9, 2025, and utilizes firm fixed pricing with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $11,893.95 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Orencia 125 mg/ml syringes. This non-set-aside competitive award is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order valued at $15,787.66 to AmerisourceBergen Drug Corp for Orencia 125 mg/ml syringes. The contract, which became effective on November 3, 2025, with an ultimate completion date of November 4, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award to the qualified vendor. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $3,570.63 on July 14, 2025, for the supply of Orencia 125 mg/ml syringes. This firm fixed price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order valued at $4,522.89 to AmerisourceBergen Drug Corp for Orencia 125 mg/ml syringes on October 17, 2025, with an ultimate completion date of October 20, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The award was made through open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Orencia 125 mg/ml syringes valued at $8,602.31 on September 2, 2025, with an ultimate completion date of September 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the major pharmaceutical distributor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Orencia 125 mg/ml syringes valued at $14,495.04. This contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was competitively awarded with no set-aside designation and utilizes firm fixed pricing. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $32,445.94 to AmerisourceBergen Drug Corp for the supply of Orencia 125 mg/ml syringes. This competitive, firm fixed-price delivery order, with an ultimate completion date of August 21, 2025, was issued without set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills the order from its corporate office location in the same municipality. The...
- The Defense Logistics Agency awarded a $7,141.26 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Orencia 125 mg/ml syringes on September 29, 2025, with completion scheduled for September 30, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery will be performed at the company's corporate office...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9BB6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,775.10 to AmerisourceBergen Drug Corp for Orencia 125 mg/mL syringes on November 10, 2025, with an ultimate completion date of November 12, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Orencia is a prescription biologic medication used primarily for treating rheumatoid arthritis and other autoimmune conditions, and its procurement through federal contract channels supports military and veteran healthcare systems. This delivery order is a child contract under AmerisourceBergen's broader $999,999,999 IDC with DLA Troop Support Medical (SPE2DX) that extends through December 2026. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement and maintains an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's track record of competitively awarded federal contracts demonstrates its capability to meet DLA's pharmaceutical supply requirements for military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.8k | 11/10/25 |